Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Prototype DNA Enzyme Drug Stops Cancer Growth

By Biotechdaily staff writers
Posted on 25 Jul 2006
While enzymes are usually proteins, a team of researchers has used a novel DNA enzyme (DNAzyme) to inhibit the c-Jun transcription factor, a principal regulator of inflammation and cancer cell growth.

A DNAzyme is a DNA molecule with a catalytic action. More...
These substances are also referred to as deoxyribozymes, DNA enzymes, and catalytic DNA. DNAzymes are associated with gene replication only, and they exist only in the laboratory, but there they are very powerful research tools. DNAzymes were first used in lead-ion dependent RNA cleaving. In the 10 or so years since, many other DNAzymes have been created, each with a specific action. DNA ligases are particularly interesting because they are exceptionally chemoselective when applied to RNA branching reactions, with each ligase adhering to only one specific branch. DNAzymes are also used as metal biosensors, detecting heavy metals completely organically.


Investigators at the University of New South Wales (Sydney, AU; www.unsw.ed.au) used the DNAzyme Dz13 to inhibit c-Jun expression in squamous cell carcinoma (SCC) cells. They found that Dz13 inhibited SCC proliferation and suppressed solid SCC tumor growth and tumor angiogenesis in severe combined immunodeficient mice. Dz13 also suppressed the expression of vascular endothelial growth factor and fibroblast growth factor-2 in the tumors. These findings were reported in the June 19, 2006, online edition of Oncogene.


In a second paper published in the July 2006 issue of Nature Biotechnology, inhibition of c-Jun by Dz13 was shown to reduce joint swelling, inflammatory cell infiltration, and bone erosion in a mouse model of rheumatoid arthritis.

"C-Jun is an important disease-causing gene,” said senior author Dr. Levon Khachigian, professor of molecular biology at the University of New South Wales. "It stands out because we do not see much of it in normal tissue, but it is highly expressed in diseased blood vessels, eyes, lungs, joints, and in the gut--in any number of areas involving inflammation and aggressive vascular growth. Our experimental drug, Dz13, is like a secret agent that finds its target, c-Jun, within the cell and destroys it. Conventional anti-inflammatory drugs are associated with a whole host of side effects. Our therapeutic may potentially avert some of these.”




Related Links:
University of New South Wales

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Urine Analyzer
respons® UDS100
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.